Targeting Reward Circuits: Psilocybin as a Novel Therapy for Residual Anhedonia
The primary objective is to evaluate whether a single dose of psilocybin (25 mg), compared to placebo, can restore fronto-striatal reward circuit function and thereby improve anhedonia and emotional blunting in individuals with residual symptoms despite ongoing SSRI or SNRI treatment. This will be assessed using precision functional mapping (PFM), task-based fMRI, and clinical rating scales (DARS).
- Status
- planned
- Phase
- Phase 1
- Institution
- NYU Langone Health
- Principal investigator
- Joshua Siegel, MD, PhD
- Start date
- 2026-07-01
- End date
- 2030-09-30
- Registry ID
- NCT07607938
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.